Anand Rotte

Oncology · 2019

A researcher in the Science corpus: 1 paper; trusts 9 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Anand Rotte trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. F. Hodi
  2. J. Wolchok
  3. C. Robert
  4. Loise M. Francisco
  5. T. Malek
  6. M. Keir
  7. D. Pardoll
  8. S. Rosenberg
  9. M. Postow
  10. Arlene H. Sharpe

Papers from Anand Rotte's perspective

Ordered by how strongly the researchers Anand Rotte trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  3. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. (The Lancet Oncology)
  4. Pembrolizumab versus Ipilimumab in Advanced Melanoma. (New England Journal of Medicine)
  5. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  6. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  7. PD-1 and its ligands in tolerance and immunity. (Annual Review of Immunology)
  8. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (Journal of Experimental Medicine)
  9. Nivolumab in previously untreated melanoma without BRAF mutation. (New England Journal of Medicine)
  10. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. (The Lancet Oncology)

Their papers